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Trends in invasive meningococcal disease in Utah dur-
ing 1995–2005 have differed substantially from US trends in 
incidence rate and serogroup and age distributions. Regional 
surveillance is essential to identify high-risk populations that 
might beneﬁ  t from targeted immunization efforts.
I
nvasive meningococcal disease (IMD) refers to the many 
illnesses caused by infection with Neisseria meningiti-
dis. IMD is an immediately reportable disease in Utah and 
a nationally reportable disease in the United States. A pre-
liminary review of IMD in Utah suggests that, since 2000, 
epidemiologic trends have occurred that are distinct from 
trends reported elsewhere in the United States. We describe 
the change in incidence rates, serogroup distribution, and 
age distribution of IMD in Utah, based on cases reported 
from 1995 through 2005, and compare our results with US 
trend data from the same period.
The Study
We studied cases of IMD that occurred from January 
1, 1995, through December 31, 2005, and were reported to 
the Utah Department of Health. Cases were classiﬁ  ed as 
conﬁ  rmed, probable, or suspected, based on the case deﬁ  -
nition for N. meningitidis infection in the Centers for Dis-
ease Control and Prevention and the Council of State and 
Territorial Epidemiologists 2005 case deﬁ  nition guidelines 
for IMD (1). Suspected cases, in which an isolate was not 
obtained, were not included in the ﬁ  nal analysis because 
this study emphasized serotyping.
Utah incidence rates were calculated by using popula-
tion estimates determined by Utah’s Indicator-Based Infor-
mation System for Public Health (2). Incidence rates and 
serogroup distributions published in the N. meningitidis 
Active Bacterial Core surveillance (ABCs) reports were 
used to estimate US trends (3).
The Pearson χ2 test and Fisher exact test were used to 
test the statistical signiﬁ  cance of the prevalence of sero-
groups by period for Utah and US data. Statistical analysis 
was performed with SAS (version 9.1; SAS Institute, Cary, 
NC, USA).
In the 10-year study period, 128 reported cases met 
the criteria of either conﬁ  rmed or probable. Yearly inci-
dence rates were calculated and ranged from a high of 
0.95/100,000 population/year to a low of 0.21/100,000 pop-
ulation/year (Figure). Because the number of annual cases 
dropped after 1999, the data were divided into 2 periods. 
The mean incidence rate decreased signiﬁ  cantly, by 63%, 
from 0.80/100,000 population/year from 1995 through 
1999 (hereafter period 1) to 0.30/100,000 population/year 
from 2000 through 2005 (hereafter period 2).
Incidence rates by period were stratified by age 
(Table 1). A rate difference was calculated by subtracting 
the average incidence rate for period 1 from the average in-
cidence rate for period 2. The highest rate for both periods 
was for infants <1 year of age (period 1, average incidence 
rate 7.98/100,000 population/year; period 2, average inci-
dence rate 3.07/100,000 population/year). The greatest rate 
difference also occurred for this age group, a decrease of 
4.91/100,000 population/year between the 2 periods’ mean 
incidence rates (Table 1).
The serogroup distribution in Utah changed substan-
tially over the course of the 2 study periods. Before 2000, 
Utah meningococcal serogroup distribution reﬂ  ected that 
of the United States; that is, serogroups B, C, and Y each 
caused ≈30% of IMD (4). Beginning in 2000, however, the 
percentage of serogroup B infections in Utah decreased 
signiﬁ  cantly to 11.3%, while serogroup Y infections in-
creased to 50.0% (p = 0.0102, Fisher exact test; χ2 = 7.2562, 
p = 0.0071). A similar change was not seen in US data. 
Whereas no signiﬁ  cant difference was observed between 
Utah and ABCs data during period 1, a signiﬁ  cant differ-
ence was seen for serogroups B (p = 0.0002) and Y (p < 
0.0001) when period 2 data were compared (Table 2). Be-
cause of an ongoing outbreak of serogroup B disease in 
Oregon, Utah data were compared with US data both with 
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and without Oregon’s numbers. For both comparisons, the 
conclusions were the same, and therefore Oregon’s num-
bers were not removed from the ﬁ  nal analysis.
No Utah cases identiﬁ  ed during the study period in-
volved residents of military barracks or college dormito-
ries, in which an increased risk for meningococcal disease 
is well documented (5,6). However, 5 (3.9%) patients were 
residents at a Job Corps facility (a residential job-training 
facility for young adults similar to a college dormitory). 
Of the 5 Job Corps cases, all were caused by serogroup Y 
infection, and 3 patients had bacteremic pneumonia.
The reduction in incidence rate could have several pos-
sible causes. One such cause could be a systematic change 
in reporting. However, no evidence to support this con-
clusion was found. Although the total number of reported 
cases declined between the 2 periods for most reporting 
hospitals, no single decline was strong enough to account 
for the observed decrease in reported cases. Underreport-
ing of cases is another possible cause, but also is unlikely. 
Data from cases of IMD reported to the Utah Department 
of Health with onset dates from January 1, 2002, through 
December 31, 2005, were compared with data extracted 
from computerized laboratory records of a large hospital 
corporation in Utah for the same period. Ten cases of IMD 
were identiﬁ  ed in each system, and demographic informa-
tion conﬁ  rmed that they were the same 10 patients.
Vaccination is unlikely to be the cause of the reduc-
tion in incidence rate as well. Over the study period, the 
percentage of vaccine-preventable strains causing disease 
in Utah increased, while infections caused by serogroup B, 
which is not included in the vaccine formula, decreased. 
Additionally, the greatest decrease in age-speciﬁ  c  inci-
dence rates occurred in age groups for which vaccination 
was not indicated.
Therefore, the decrease in the incidence rate seen is 
most likely the result of ﬂ  uctuations in the community in-
cidence rate, for which oscillations with a cyclical pattern 
have been documented (7–9). The incidence rate of IMD 
in Utah in 2005 increased substantially from the rate ob-
served in 2004 (Figure). Although this rate is still much 
lower than rates seen for any year in period 1, it is still 
much greater than any other rate observed in period 2; the 
incidence rate appears to be increasing again, while the se-
rogroup distribution is not changing. Due to the cyclical 
pattern of meningococcal disease, variability is expected, 
but the increase in serogroup Y cases and decrease in sero-
group B cases appear unique to Utah.
Conclusions
During the second study period (2000–2005), the inci-
dence rate and age and serogroup distributions for IMD in 
Utah have differed from US trends. In Utah, the decrease 
in serogroup B infections, the most common cause of IMD 
in infants, resulted in an overall decrease in infections in 
infants and increased infection rates in adolescents and 
young adults ages 15 to 24 years. Furthermore, of the 38 
serogrouped isolates from period 2, 31 (82%) were vac-
cine-preventable strains. This suggests that recommenda-
tions by the Advisory Committee on Immunization Prac-
tices (ACIP) for routine vaccination of selected cohorts 
Table 1. Rates of invasive meningococcal disease by age group, Utah, 1995–2005* 
Age, y  No. period 1 cases  No. period 2 cases  Period 1 rate/100,000  Period 2 rate/100,000  Rate difference 
<1 17 9 7.98 3.07  4.91
1–4 14 4 1.75 0.36  1.39
5–14 10 4 0.53 0.17  0.37
15–24 20 15 1.03 0.58  0.45
25–34 4 3 0.25 0.26 0.01
35–44 6 2 0.40 0.11  0.29
45–54 4 2 0.39 0.13  0.26
55–64 3 2 0.48 0.20  0.27
65–74 3 1 0.61 0.16  0.46
75–84 2 1 0.66 0.24  0.42
>85 1 1 1.03 0.68  0.35
Total 84 44 0.80 0.30  0.50
*Period 1, 1995–1999; period 2, 2000–2005. 
Table 2. Serogroup distribution of invasive meningococcal disease by period* 
Period 1  Period 2 
Neisseria meningitidis serogroup  Utah United States  p value  Utah United States  p value 
B 32.1% 29.2% 0.5701 11.3% 39.7%  0.0002 
Y 26.1% 32.0% 0.2773 50.0% 23.9% <0.0001
C 25.0% 25.5% 0.9298 15.9% 21.4%  0.3783 
Other 16.7% 13.4% 0.4084 22.7% 15.0%  0.1633 
*Period 1, 1995–1999; period 2, 2000–2005. US data estimates based on information collected from Active Bacterial Core surveillance sites.  Invasive Meningococcal Disease, Utah 
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with meningococcal conjugate vaccine (MCV-4) would be 
beneﬁ  cial in Utah. ACIP recommendations, however, may 
not reﬂ  ect regional epidemiologic trends. For example, Job 
Corp residents were identiﬁ  ed as a high-risk population for 
IMD in Utah but have not been identiﬁ  ed as a high-risk 
group in the United States. Because IMD is so rare, routine 
vaccination is costly (10), and vaccine supply is limited, 
we believe regional surveillance is a key factor in deter-
mining groups at high risk for IMD. The identiﬁ  cation of 
serogroup Y disease among Job Corps residents inﬂ  uenced 
Utah’s vaccine policy. This study emphasizes the need for 
continued regional surveillance to help direct vaccine poli-
cy especially in regions of the United States not represented 
in ABCs.
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